Dr. Chris Dakhil has been recognized as an author in a trial that focused on preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV). CINV, when associated with highly emetogenic chemotherapy (HEC) unfavorably has affects on the quality of life of patients. This can, in some cases, even affect chemotherapy compliance. This specific MAGIC trial was a “prospective, multicenter, randomized, double-blind, double-dummy, parallel-group trial” conducted throughout 77 sites in the U.S. This trial concluded after a year and has resulted in the superiority of APF 530 injection versus ondansetron medication in the prevention of CINV following HEC. CCK is proud to say our physicians are committed to staying up to date and active in oncology research in order to bring the best care to their patients. CCK is one of only 46 cancer research programs in the nation currently funded by the National Cancer Institute Community Oncology Research Program (NCORP). NCORP is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems and conduct high quality trials that are aimed to better understand oncology through studies that work to prevent and/ or care for cancer.
The article is available in it’s entirety below or online at https://www.dovepress.com/articles.php?article_id=32943
Manuscript published by DoveMedicalPress
